ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,891Medicare Part D Prescriptions Filled, Including Refills

Rank: 73 out of 337

$523K Total Retail Price of All Prescriptions

Rank: 66 out of 337

500 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 500 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 500 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

2% of this provider’s 8,357 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
OMEPRAZOLE 620 525 1 4
LISINOPRIL 339 314 2 2
SIMVASTATIN 314 277 3 1
LEVOTHYROXINE SODIUM 282 249 4 5
AMLODIPINE BESYLATE 269 265 5 3
METOPROLOL TARTRATE 222 201 6 6
LOSARTAN POTASSIUM 210 195 7 15
FUROSEMIDE 209 180 8 8
PREDNISONE 207 183 9 40
HYDROCHLOROTHIAZIDE 199 177 10 9
ATORVASTATIN CALCIUM 191 163 11 7
RANITIDINE HCL 175 126 12 30
METFORMIN HCL 172 162 13 12
HYDROCODONE-ACETAMINOPHEN 169 109 S3 14 13
ZOLPIDEM TARTRATE 145 124 15 23
LEVOXYL 144 133 16 90
PANTOPRAZOLE SODIUM 128 73 17 36
CITALOPRAM HBR 123 119 18 17
ATENOLOL 114 109 19 10
SERTRALINE HCL 112 100 20 18
AMITRIPTYLINE HCL 94 63 R 21 75
GABAPENTIN 92 67 22 20
NEXIUM 91 76 23 56
DILTIAZEM 24HR ER 90 79 24 76
CRESTOR 89 88 25 29
WARFARIN SODIUM 85 74 26 11
FLUTICASONE PROPIONATE 81 62 27 34
DIOVAN 81 81 27 26
ALLOPURINOL 79 79 29 28
GLIPIZIDE ER 79 70 29 69
GLIPIZIDE 78 78 31 45
TRAMADOL HCL 78 75 31 32
MELOXICAM 77 63 33 54
CLOPIDOGREL 75 75 34 42
PROAIR HFA 73 47 35 38
VENLAFAXINE HCL ER 72 45 36 86
LISINOPRIL-HYDROCHLOROTHIAZIDE 72 72 36 31
SINGULAIR 71 42 38 113
FENOFIBRATE 71 40 38 48
TRAZODONE HCL 68 52 40 16
LIPITOR 66 66 41 33
DONEPEZIL HCL 65 65 42 22
CIPROFLOXACIN HCL 63 52 43 71
AZITHROMYCIN 60 47 44 51
DIOVAN HCT 59 55 45 88
POLYETHYLENE GLYCOL 3350 56 44 46 47
ADVAIR DISKUS 56 48 46 44
PAROXETINE HCL 56 56 46 46
SYMBICORT 54 46 49 151
BISOPROLOL FUMARATE 53 51 50 67
SYNTHROID 52 38 51 41
CYMBALTA 50 35 52 59
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 6, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.